PRIMA-1 Reactivates Mutant p53 by Covalent Binding to the Core Domain

Cancer Cell

Volumn 15, Issue 5, 2009, Pages 376-388

  Lambert, Jeremy M R ^a,b   Gorzov, Petr ^a   Veprintsev, Dimitry B ^c   Söderqvist, Maja ^a   Segerbäck, Dan ^a   Bergman, Jan ^a   Fersht, Alan R ^c   Hainaut, Pierre ^b   Wiman, Klas G ^a   Bykov, Vladimir J N ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

CELLCYCLE; CHEMBIO

Indexed keywords

PROLIN RICH MEMBRANE ANCHOR 1; PROTEIN P53; THIOL GROUP; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; COVALENT BOND; HUMAN; HUMAN CELL; MOLECULAR LIBRARY; MOUSE; MUTANT; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; PROTEIN TARGETING; REGULATORY MECHANISM; TUMOR CELL;

EID: 65449144050     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.03.003     Document Type: Article

References (34)

1. Bass D.A., Parce J.W., Dechatelet L.R., Szejda P., Seeds M.C., and Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. J. Immunol. 130 (1983) 1910-1917
2. Bykov V.J., Issaeva N., Selivanova G., and Wiman K.G. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis 23 (2002) 2011-2018
3. Bykov V.J., Issaeva N., Shilov A., Hultcrantz M., Pugacheva E., Chumakov P., Bergman J., Wiman K.G., and Selivanova G. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. 8 (2002) 282-288
4. Bykov V.J., Issaeva N., Zache N., Shilov A., Hultcrantz M., Bergman J., Selivanova G., and Wiman K.G. Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs. J. Biol. Chem. 280 (2005) 30384-30391
5. Bykov V.J., Zache N., Stridh H., Westman J., Bergman J., Selivanova G., and Wiman K.G. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 24 (2005) 3484-3491
6. Chipuk J.E., Maurer U., Green D.R., and Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Cell 4 (2003) 371-381
7. Cho Y., Gorina S., Jeffrey P.D., and Pavletich N.P. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265 (1994) 346-355
8. Ellman G.L. Tissue sulfhydryl groups. Arch. Biochem. Biophys. 82 (1959) 70-77
9. Foster B.A., Coffey H.A., Morin M.J., and Rastinejad F. Pharmacological rescue of mutant p53 conformation and function. Science 286 (1999) 2507-2510
10. Hollstein M., Sidransky D., Vogelstein B., and Harris C.C. p53 mutations in human cancers. Science 253 (1991) 49-53
11. Jayaraman L., Murthy K.G., Zhu C., Curran T., Xanthoudakis S., and Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes Dev. 11 (1997) 558-570
12. Joerger A.C., Ang H.C., Veprintsev D.B., Blair C.M., and Fersht A.R. Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J. Biol. Chem. 280 (2005) 16030-16037
13. Johnson T.M., Yu Z.X., Ferrans V.J., Lowenstein R.A., and Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl. Acad. Sci. USA 93 (1996) 11848-11852
14. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. USA 102 (2005) 7665-7670
15. Lane D. Curing cancer with p53. N. Engl. J. Med. 350 (2004) 2711-2712
16. Martins C.P., Brown-Swigart L., and Evan G.I. Modeling the Therapeutic Efficacy of p53 Restoration in Tumors. Cell 127 (2006) 1323-1334
17. Merwin J.R., Mustacich D.J., Muller E.G., Pearson G.D., and Merrill G.F. Reporter gene transactivation by human p53 is inhibited in thioredoxin reductase null yeast by a mechanism associated with thioredoxin oxidation and independent of changes in the redox state of glutathione. Carcinogenesis 23 (2002) 1609-1615
18. Nahi H., Lehmann S., Mollgard L., Bengtzen S., Selivanova G., Wiman K.G., Paul C., and Merup M. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Br. J. Haematol. 127 (2004) 285-291
19. Nahi H., Merup M., Lehmann S., Bengtzen S., Mollgard L., Selivanova G., Wiman K.G., and Paul C. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Br. J. Haematol. 132 (2006) 230-236
20. North S., Pluquet O., Maurici D., El-Ghissassi F., and Hainaut P. Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1. Mol. Carcinog. 33 (2002) 181-188
21. Olivier M., Eeles R., Hollstein M., Khan M.A., Harris C.C., and Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum. Mutat. 19 (2002) 607-614
22. Olivier M., Langerod A., Carrieri P., Bergh J., Klaar S., Eyfjord J., Theillet C., Rodriguez C., Lidereau R., Bieche I., et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 12 (2006) 1157-1167
23. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., and Vogelstein B. A model for p53-induced apoptosis. Nature 389 (1997) 300-305
24. Quesenberry M.S., and Lee Y.C. A rapid formaldehyde assay using purpald reagent: application under periodation conditions. Anal. Biochem. 234 (1996) 50-55
25. Reddy N.L., Hill J., Ye L., Fernandes P.B., and Stout D.M. Identification and structure-activity relationship studies of 3-methylene-2-norbornanone as potent anti-proliferative agents presumably working through p53 mediated apoptosis. Bioorg. Med. Chem. Lett. 14 (2004) 5645-5649
26. Rehman A., Chahal M., Tang X., Bruce J., Pommier Y., and Daoud S. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res. 7 (2005) R765-R774
27. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., and Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 11 (2005) 1306-1313
28. Seemann S., and Hainaut P. Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. Oncogene 24 (2005) 3853-3863
29. Shen H., Chen Z.J., Zilfou J.T., Hopper E., Murphy M., and Tew K.D. Binding of the aminothiol WR-1065 to transcription factors influences cellular response to anticancer drugs. J. Pharmacol. Exp. Ther. 297 (2001) 1067-1073
30. Sun X.Z., Vinci C., Makmura L., Han S., Tran D., Nguyen J., Hamann M., Grazziani S., Sheppard S., Gutova M., et al. Formation of disulfide bond in p53 correlates with inhibition of DNA binding and tetramerization. Antioxid. Redox Signal. 5 (2003) 655-665
31. Ventura A., Kirsch D.G., McLaughlin M.E., Tuveson D.A., Grimm J., Lintault L., Newman J., Reczek E.E., Weissleder R., and Jacks T. Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007) 661-665
32. Vousden K.H., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
33. Xue W., Zender L., Miething C., Dickins R.A., Hernando E., Krizhanovsky V., Cordon-Cardo C., and Lowe S.W. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007) 656-660
34. Zache N., Lambert J.M.R., Rökaeus N., Shen J., Hainaut P., Bergman J., Wiman K.G., and Bykov V.J.N. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol. Oncol. 2 (2008) 70-80